IRD (Opus Genetics) Float Percentage Of Total Shares Outstanding: 95.06% (As of Jun. 28, 2026)


IRD Opus Genetics Inc IRD
24 GF Score
Price $4.00
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Opus Genetics Float Percentage Of Total Shares Outstanding?

Opus Genetics IRD +7.38% 24 Float Percentage Of Total Shares Outstanding is 95.06% as of Jun. 28, 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Opus Genetics's float shares is 78.49 Mil. Opus Genetics's total shares outstanding is 82.57 Mil. Opus Genetics's float percentage of total shares outstanding is 95.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Opus Genetics's Insider Ownership is 11.18%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Opus Genetics's Institutional Ownership is 66.87%.

IRD
24GF Score
Opus Genetics Inc IRD
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Opus Genetics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Opus Genetics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=78.49/82.57
=95.06%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 95.06% mean?
Opus Genetics (IRD) has a Float Percentage Of Total Shares Outstanding of 95.06% as of Jun. 28, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Opus Genetics and its competitors.
Is Opus Genetics' Float Percentage Of Total Shares Outstanding too high?
Opus Genetics' current Float Percentage Of Total Shares Outstanding is 95.06%. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Float Percentage Of Total Shares Outstanding compare to IFRX and RGNX?
Opus Genetics' Float Percentage Of Total Shares Outstanding of 95.06% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Opus Genetics and its competitors. Opus Genetics's current Float Percentage Of Total Shares Outstanding is 95.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $4.00 — trading 981.1% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 95.06%. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Opus Genetics (IRD), the current Float Percentage Of Total Shares Outstanding is 95.06% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $4.00 is trading 981.1% above its estimated GF Value™ of $0.37. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • Float Percentage Of Total Shares Outstanding: 95.06%
  • GF Value™: $0.37 vs. price of $4.00 (981.1% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score

Get the complete analysis for IRD

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00
Price
$0.37
GF Value